Resultados de la búsqueda 431-440 of 9591 for Hepatitis C
Page 1.
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...
The purpose of this study is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD and ...
The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's transformation, ...
Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs ...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...
https://www.cdc.gov/hepatitis/hbv/bfaq.htm. Accessed March 4, 2019. Hepatitis C questions and answers for the public. Centers for Disease Control and ...
Para buscar a un miembro del personal cuyo nombre comienza con la letra C C ... No hay ningún miembro del personal c. Mayo Clinic Privacy Policy. En Mayo ...
Rochester, Minn. This is a study to generate feasibilty data regarding the collection of health and psychosocial outcomes after acquired spinal cord injury (SCI) ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.